{"preliminary_commentary":{"by_channel":{"x_thread":8},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05710406\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"A022004","nct_id":"NCT05710406","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=a022004-nct05710406. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive encorafenib PO QD on days 1-28 and cetuximab IV on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for a total of 6 cycles in the absence of disease recurrence or unacceptable toxicity. Patients also undergo collection of blood samples throughout the study and CT or MRI during screening and follow-up.","label":"Arm I (encorafenib, cetuximab)","type":"EXPERIMENTAL"},{"description":"Patients undergo observation per usual care on study. Patients also undergo collection of blood samples throughout the study and CT or MRI during screening and follow-up.","label":"Arm II (patient observation)","type":"ACTIVE_COMPARATOR"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2034-06-01","type":"ESTIMATED"},"conditions":["Colon Adenocarcinoma","Microsatellite Stable Colon Carcinoma","Stage IIB Colon Cancer AJCC v8","Stage IIC Colon Cancer AJCC v8","Stage III Colon Cancer AJCC v8"],"enrollment":{"count":1,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Encorafenib","otherNames":["Braftovi","LGX-818"],"type":"DRUG"},{"name":"Cetuximab","otherNames":["Cetuximab Biosimilar CDP-1","Cetuximab Biosimilar KL 140","Chimeric Monoclonal Antibody C225","Erbitux"],"type":"BIOLOGICAL"},{"name":"Biospecimen Collection","otherNames":[],"type":"PROCEDURE"},{"name":"Computed Tomography","otherNames":["CAT Scan","CT Scan"],"type":"PROCEDURE"},{"name":"Magnetic Resonance Imaging","otherNames":["MRI"],"type":"PROCEDURE"},{"name":"Patient Observation","otherNames":["Watchful Waiting"],"type":"OTHER"}],"last_update":"2026-07-02","lead_sponsor":"Alliance for Clinical Trials in Oncology","official_title":"Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2034-06-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Circulating tumor deoxyribonucleic acid (ctDNA) clearance rate (Phase II; ctDNA positive cohort)","timeFrame":"At 6 months after randomization"},{"measure":"tDNA recurrence-free survival rate (ctDNA-RFS) (Phase II; ctDNA negative cohort)","timeFrame":"at 6 months after randomization"},{"measure":"Disease free survival (DFS) (Phase III)","timeFrame":"Assessed up to 6 years after randomization"}],"references":[],"start_date":{"date":"2023-08-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer","url":"https://clinicaltrials.gov/study/NCT05710406"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/a022004-nct05710406"}